1. physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely 2. known severe liver disease (eg, child pugh score \> 12, ast \>5 times upper limit) 3. sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio \< 300 mghg 4. known allergic reaction to camostat mesilate or one of its excipients 5. known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m\^2) or receiving dialysis 6. pregnant or breastfeeding, or positive pregnancy test in a predose examination 7. receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. 8. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)

1. physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely 2. known severe liver disease (eg, child pugh score \> 12, ast \>5 times upper limit) 3. sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio \< 300 mghg 4. known allergic reaction to camostat mesilate or one of its excipients 5. known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m\^2) or receiving dialysis 6. pregnant or breastfeeding, or positive pregnancy test in a predose examination 7. receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. 8. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)

physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely known severe liver disease (eg, child pugh score > 12, ast >5 times upper limit) sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio < 300 mghg known allergic reaction to camostat mesilate or one of its excipients known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m^2) or receiving dialysis pregnant or breastfeeding, or positive pregnancy test in a predose examination receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)

physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely known severe liver disease (eg, child pugh score > 12, ast >5 times upper limit) sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio < 300 mghg known allergic reaction to camostat mesilate or one of its excipients known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m^2) or receiving dialysis pregnant or breastfeeding, or positive pregnancy test in a predose examination receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)

1. physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely 2. known severe liver disease (eg, child pugh score > 12, ast >5 times upper limit) 3. sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio < 300 mghg 4. known allergic reaction to camostat mesilate or one of its excipients 5. known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m^2) or receiving dialysis 6. pregnant or breastfeeding, or positive pregnancy test in a predose examination 7. receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. 8. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)

1. physician makes a decision that trial involvement is not in participants' best interest, or has any condition that does not allow the protocol to be followed safely 2. known severe liver disease (eg, child pugh score > 12, ast >5 times upper limit) 3. sao2/spo2 ≤94% on room air condition, or the pa02/fi02 ratio < 300 mghg 4. known allergic reaction to camostat mesilate or one of its excipients 5. known severe renal impairment (estimated glomerular filtration rate ≤30 ml/min/1.73 m^2) or receiving dialysis 6. pregnant or breastfeeding, or positive pregnancy test in a predose examination 7. receipt of any experimental treatment for covid-19, including agents with demonstrated or possible direct acting antiviral activity, including, but not limited to, remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin, within the 30 days prior to the time of the screening evaluation. no off label use of a drug for covid 19 is allowed. 8. history of human immunodeficiency virus infection on highly active antiretroviral therapy (haart)